An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
Maria Sole Chimenti,1,* Arianna D’Antonio,1,* Paola Conigliaro,1 Sara Ferrigno,1 Andrea Vendola,1 Mario Ferraioli,1 Paola Triggianese,1 Luisa Costa,2 Francesco Caso,2 Roberto Perricone1 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome T...
Saved in:
Main Authors: | Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/9c4966ba5d5b4b01b44f285dac251f29 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019) -
The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
by: Georgios Kokolakis, et al.
Published: (2021) -
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
by: D'Angelo S, et al.
Published: (2017) -
Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients
by: Song Zhang, et al.
Published: (2021) -
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
by: Harrington R, et al.
Published: (2020)